ADIPOLIVE

Recruiting

Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD

Region-specific Adipose Tissues and Liver Changes Associated With Semaglutide Treatment in Chronic Kidney Disease Patients

Lead sponsor

University of Alberta

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Chronic kidney disease, Type 2 diabetes

Key I/E criterion

•eGFR 60-89

Primary endpoint

•Correlation between kidney disease progression and cardiometabolic changes

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07187830

Org study IDU1111-1328-1600

Timeline

Milestones

Study first posted2025-09-23actual

Study start2026-02-23actual

Last update posted2026-05-11actual

Primary completion2027-12-15estimated

Study completion2028-01-15estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Chronic kidney diseaseType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodProbability sample

Study population text

Investigators will enroll patients with diabetic kidney disease at different stages of CKD receiving the GLP-1RA Semaglutide or SoC regimen, depending on their medical indication and cardiometabolic and hepatic steatosis stage.

Inclusion criteria

•Patients ≥ 18 years of age.

•Patients diagnosed with T2DM (>18 months) and CKD in stages G1, G2, G3a, G3b and G4; the CKD staging will be established according to the eGFR as per the KDIGO guidelines (G1: eGFR ≥90 ml/min/1.73m2; G2: 60-89 ml/min/1.73m2; G3a: 45-59 ml/min/1.73m2; G3b: 30-44 ml/ min/1.73m2; G4: 15-29 ml/ min/1.73m2).

•Patients with T2DM and CKD, with or without semaglutide treatment.

•Patients who voluntarily agree to participate and sign informed consent.

Exclusion criteria

•Patients <18 years of age.

•Pregnant, breastfeeding, or an intention of becoming pregnant or not using adequate contraceptive measures (including country-specific adequate measures, if any)

•Patients diagnosed with T2DM and CKD in stage G5 or stage G4 requiring dialysis as per KDIGO guidelines.

•Previous participation in this trial (screened or randomized)

•Patients diagnosed with neuropsychiatric diseases that prevent them from understanding the benefits/risks associated with the project or voluntarily choosing to participate.

•Known or suspected allergy to trial medication(s), excipients, or related products

•Contraindications to study medication(s), worded specifically as stated in the Product Monograph

•Refusal to participate or consent revocation.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

2 endpoints

Primary/protocol endpoint/low confidence

Correlation between kidney disease progression and cardiometabolic changes

Time frame:From enrollment to the end of follow-up at 12 months

descriptive

Secondary/protocol endpoint/low confidence

Adiposopathy biomarkers in different CKD stages

Time frame:From enrollment to the end of follow-up at 12 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.